Emberton M - Search Results

1

Is it time to consider a role for MRI before prostate biopsy?

Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C, Emberton M. Ahmed HU, et al. Among authors: emberton m. Nat Rev Clin Oncol. 2009 Apr;6(4):197-206. doi: 10.1038/nrclinonc.2009.18. Nat Rev Clin Oncol. 2009. PMID: 19333226 Review.

2

Bile duct injury following laparoscopic cholecystectomy.

Cheslyn-Curtis S, Emberton M, Ahmed H, Williamson RC, Habib NA. Cheslyn-Curtis S, et al. Among authors: emberton m. Br J Surg. 1992 Mar;79(3):231-2. doi: 10.1002/bjs.1800790314. Br J Surg. 1992. PMID: 1532527 No abstract available.

3

A rare tumour in the pelvis presenting with lower urinary symptoms: 'sclerosing epithelioid fibrosarcoma'.

Arya M, Garcia-Montes F, Patel HR, Emberton M, Mundy AR. Arya M, et al. Among authors: emberton m. Eur J Surg Oncol. 2001 Feb;27(1):121-2. doi: 10.1053/ejso.2000.1023. Eur J Surg Oncol. 2001. PMID: 11237504 No abstract available.

4

Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer.

Moore CM, Nathan TR, Lees WR, Mosse CA, Freeman A, Emberton M, Bown SG. Moore CM, et al. Among authors: emberton m. Lasers Surg Med. 2006 Jun;38(5):356-63. doi: 10.1002/lsm.20275. Lasers Surg Med. 2006. PMID: 16392142 Clinical Trial.

5

How good is MRI at detecting and characterising cancer within the prostate?

Kirkham AP, Emberton M, Allen C. Kirkham AP, et al. Among authors: emberton m. Eur Urol. 2006 Dec;50(6):1163-74; discussion 1175. doi: 10.1016/j.eururo.2006.06.025. Epub 2006 Jun 30. Eur Urol. 2006. PMID: 16842903 Review.

6

The effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapy.

Uchida T, Illing RO, Cathcart PJ, Emberton M. Uchida T, et al. Among authors: emberton m. BJU Int. 2006 Oct;98(4):770-2. doi: 10.1111/j.1464-410X.2006.06369.x. Epub 2006 Jul 28. BJU Int. 2006. PMID: 16879448

7

Deciding the future of British urology.

Illing RO, Emberton M. Illing RO, et al. Among authors: emberton m. BJU Int. 2006 Aug;98(2):252-3. doi: 10.1111/j.1464-410X.2006.06292.x. BJU Int. 2006. PMID: 16879660 No abstract available.

8

To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?

Uchida T, Illing RO, Cathcart PJ, Emberton M. Uchida T, et al. Among authors: emberton m. BJU Int. 2006 Sep;98(3):537-9. doi: 10.1111/j.1464-410X.2006.06297.x. BJU Int. 2006. PMID: 16925749

9

Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: A proposed standard for the conduct of therapy.

Illing RO, Leslie TA, Kennedy JE, Calleary JG, Ogden CW, Emberton M. Illing RO, et al. Among authors: emberton m. BJU Int. 2006 Dec;98(6):1187-92. doi: 10.1111/j.1464-410X.2006.06509.x. BJU Int. 2006. PMID: 17125476

10

Sonablate-500: transrectal high-intensity focused ultrasound for the treatment of prostate cancer.

Illing R, Emberton M. Illing R, et al. Among authors: emberton m. Expert Rev Med Devices. 2006 Nov;3(6):717-29. doi: 10.1586/17434440.3.6.717. Expert Rev Med Devices. 2006. PMID: 17280536 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

567 results

Search Page

Filters